Drugs / ALV-100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07399678 | Dec 2025 → Apr 2027 expected | type 2 diabetes mellitus | Alveus Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-01-23 | Alveus Therapeutics, Inc. | Regulatory Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 for Obesity alveustx.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-01-23 | Alveus Therapeutics, Inc. | Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 for Obesity alveustx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALV-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07399678 ↗ |
| Route | Subcutaneous | “by subcutaneous injection.” NCT07399678 ↗ |